首页分子通1-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-3-[3-isopropyl-1'-(2-pyrrolidin-1-ylethyl)-1'H-[1,4']bipyrazolyl-5-yl]urea formate salt
1-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-3-[3-isopropyl-1'-(2-pyrrolidin-1-ylethyl)-1'H-[1,4']bipyrazolyl-5-yl]urea formate salt
1-{(1S,4R)-4-[3-((2S,6R)-2,6-dimethylpiperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydronaphthalen-1-yl}-3-[3-isopropyl-1'-(2-pyrrolidin-1-ylethyl)-1'H-[1,4']bipyrazolyl-5-yl]urea formate salt
Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.